Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps
Authors:
Open Access
- 20 April 2023
- journal article
- Published by BMJ in BMJ Oncology
- Vol. 2 (1) , e000039
Abstract
Long-term screening with serum prostate-specific antigen (PSA) and systematic prostate biopsies can reduce prostate cancer mortality but leads to unacceptable overdiagnosis. Over the past decade, diagnostic methods have improved and the indolent nature of low-grade prostate cancer has been established. These advances now enable more selective detection of potentially lethal prostate cancer. This non-systematic review summarises relevant diagnostic advances, previous and ongoing screening trials, healthcare policies and important remaining knowledge gaps. Evidence synthesis and conclusions: The strong association between low serum PSA values and minimal long-term risk of prostate cancer death allows for adjusting screening intervals. Use of risk calculators, biomarkers and MRI to select men with a raised PSA value for biopsy and lesion-targeting rather than systematic prostate biopsies reduce the detection of low-grade cancer and thereby overdiagnosis. These improvements recently led the European Union to recommend its member states to evaluate the feasibility and effectiveness of organised screening programmes for prostate cancer. Nonetheless, important knowledge gaps remain such as the performance of modern diagnostic methods in long-term screening programmes and their impact on mortality. The knowledge gaps are currently being addressed in three large randomised screening trials. Population-based pilot programmes will contribute critical practical experience.Keywords
Funding Information
- Pirkanmaan Sairaanhoitopiiri (Not applicable)
- National Institutes of Health (R01-CA244948, P30-CA008748, U01-CA266535)
- Västra Götalandsregionen (ALF Pj 274255, VGFOUREG-969400)
- Syöpäsäätiö (Not applicable)
- Research Council of Finland (Not applicable)
- Päivikki ja Sakari Sohlbergin Säätiö (Not applicable)
- Cancerfonden (20 1354 PjF)
This publication has 129 references indexed in Scilit:
- A prospective study of socioeconomic status, prostate cancer screening and incidence among men at high risk for prostate cancerCancer Causes & Control, 2012
- Prostate-Cancer Mortality at 11 Years of Follow-upNew England Journal of Medicine, 2012
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI: Journal of the National Cancer Institute, 2012
- Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative groupWorld Journal of Urology, 2011
- Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control studyBMJ, 2010
- [-2]Proenzyme Prostate Specific Antigen is More Accurate Than Total and Free Prostate Specific Antigen in Differentiating Prostate Cancer From Benign Disease in a Prospective Prostate Cancer Screening StudyJournal of Urology, 2010
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Development and Internal Validation of a Nomogram Predicting the Probability of Prostate Cancer Gleason Sum Upgrading Between Biopsy and Radical Prostatectomy PathologyEuropean Urology, 2006
- Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screeningInternational Journal of Cancer, 2004
- Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the ProstateNew England Journal of Medicine, 1987